MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026)

MoonLake Immunotherapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $254.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 38.43% year-over-year to $254.0 million; the TTM figure through Mar 2026 stood at $254.0 million (down 38.43% YoY), while the FY2025 annual figure was $304.5 million, down 32.84% from the prior year.
• Common Equity for Q1 2026 stood at $254.0 million, down from $304.5 million in the prior quarter.
• The five-year high for Common Equity was $552.4 million in Q1 2024, with the low at -$25.3 million in Q1 2022.
• The 5-year median for Common Equity is $357.9 million (2025), against an average of $319.6 million.
• Peak annual rise in Common Equity reached 11310.99% in 2022, while the deepest fall reached 10205.8% in 2022.
• MoonLake Immunotherapeutics' Common Equity stood at $68.8 million in 2022, then soared by 646.71% to $513.5 million in 2023, then decreased by 11.7% to $453.4 million in 2024, then sank by 32.84% to $304.5 million in 2025, then slipped by 16.57% to $254.0 million in 2026.
• Business Quant data shows MLTX's Common Equity at $254.0 million in Q1 2026, $304.5 million in Q4 2025, and $291.2 million in Q3 2025.